Icatibant Aspire Pharma (Icatibant)

Icatibant works as a competitive antagonist of the bradykinin B2 receptor. By binding to this receptor, it prevents bradykinin from causing vasodilation and increased vascular permeability, which are the primary mechanisms that lead to the swelling seen in hereditary angioedema.

The dose of icatibant is determined by the prescribing healthcare professional based on the patient’s condition and clinical guidelines. Typically, it is administered as a single subcutaneous injection during an acute hereditary angioedema attack, with additional doses considered only under medical supervision.

Safety data for icatibant in pregnancy and lactation are limited. It should only be used when the potential benefit justifies the potential risk to the fetus or infant. Healthcare providers will weigh the clinical need against the unknown safety profile.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain logistics if needed), and any required import documentation.

The primary alternative for hereditary angioedema is C1‑inhibitor concentrate, which replaces the deficient protein. Icatibant directly blocks the bradykinin B2 receptor, offering a rapid, protein‑free option. Both are effective, but icatibant is administered subcutaneously and does not require plasma‑derived products, whereas C1‑inhibitor is given intravenously.

Icatibant should be stored refrigerated at 2‑8 °C (36‑46 °F). Keep the vials in their original packaging, protect them from light, and avoid freezing or shaking. If temporary storage at room temperature is unavoidable, limit exposure to no more than 30 °C for a short period, then return to refrigeration promptly.

Icatibant is given as a subcutaneous injection, usually into the abdomen or thigh. The injection site should be cleaned with an alcohol swab, and the needle inserted at a 45‑90° angle depending on the needle length. Patients or caregivers are trained on proper technique to ensure safe and effective delivery.

The most serious risks include severe hypersensitivity reactions such as anaphylaxis, airway edema that could compromise breathing, and profound hypotension. Patients should be monitored closely after injection, and any signs of difficulty breathing, swelling of the face or throat, or sudden drop in blood pressure require immediate medical attention.

Icatibant is contraindicated in individuals with known hypersensitivity to icatibant or any of its excipients. It should also be used with caution in patients who have experienced angioedema related to ACE‑inhibitor therapy, as the underlying mechanism may increase the risk of adverse reactions.